Article Detail - JE Part B
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R13 - Effective October 1, 2025
Date Posted: September 4, 2025
This Billing and Coding Article has been revised under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).
Effective Date: October 1, 2025
Summary of Changes:
Under ICD-10 Codes that Support Medical Necessity Group 1: Codes added Z85.4A. Under ICD-10 Codes that Support Medical Necessity Group 2: Codes added Z85.4A. This revision is due to the Annual ICD-10-CM Update and will become effective on 10/1/2025.
Under Article Text revised Table 1 row 9 to add "Pathlight Recurrence Monitoring Bespoke Assay Design + Plasma Test (SAGA Diagnostics)". Revised row 10 to add "Pathlight Recurrence Monitoring single Plasma Test (SAGA Diagnostics)". Under subheading Additional Test-specific Indications, Limitations and Instructions revised 2nd sentence to add "Pathlight". Under ICD-10 Codes that Support Medical Necessity Group 3: Codes added Z85.3 This revision is due to a new covered test that has successfully completed a TA and is effective for 3/28/2025.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.
